1. Atrial Mechanics, Atrial Cardiomyopathy and Impact of Atrial Interventions.
- Author
-
Kittipibul V, Laufer-Perl M, Balakumaran K, Costanzo MR, Marwick TH, Alenezi F, Mohan RC, Thohan V, Bhatt K, Friedmann RH, Smart F, Eckman PM, Saraon T, Biegus J, Paitazoglou C, Hamid N, Amin R, Tong A, and Fudim M
- Subjects
- Humans, Atrial Function physiology, Atrial Remodeling physiology, Catheter Ablation methods, Atrial Fibrillation physiopathology, Atrial Fibrillation therapy, Heart Atria physiopathology, Cardiomyopathies physiopathology, Cardiomyopathies etiology
- Abstract
Our comprehension of atrial mechanics, atrial cardiomyopathy and their clinical implications across various cardiovascular conditions has advanced significantly. Atrial interventions can have differing effects on atrial mechanics. With the rapid increase in the use of atrial interventions, it is crucial for investigators and clinicians to acknowledge the potential adverse effects of these interventions on atrial mechanics that might not be clinically significant at the time of interventions. Recognizing the preclinical stage of atrial maladaptation might enable early interventions before the development of irreversible atrial remodeling and clinical manifestation. We review normal atrial function and mechanics, and atrial cardiomyopathy in select cardiovascular conditions. We also summarize and discuss the current evidence of the impact of various atrial interventions on atrial function and mechanics., Competing Interests: Disclosures ML-P has received speaker honoraria from BI, AstraZeneca, Novartis, Pfizer, Novonordisk, Abbvie, Bayer, Medison, V-wave, and Alleviant and has served as a consultant to BI, Astrazeneca and Bayer, receives research grants from BI, AstraZeneca, Novartis, Pfizer, and Bayer. THM is supported by an Investigator grant (2008129) from the National Health and Medical Research Council (Canberra, Australian Capital Territory, Australia). MR has received research support from Corvia and V-Wave paid to the institution. VT is a consultant for Abbott, Impulse Dynamics and Battelle and participated in speaker's bureaus for Pfizer and Boehringer Ingelheim. KB is on the speaker's bureau for Abbott, Pfizer and Novartis and is a consultant for Abbott. FS has received research grants from Amgen and is a consultant for Abbott. AT has received speaker honoraria from Bristol-Myers Squibb. MF is supported by the NIH (1OT2HL156812-01; 1R01HL171305-01) and Doris Duke and has received consulting fees from Abbott, Ajax, Alio Health, Alleviant, Artha, Audicor, AxonTherapies, Bayer, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardioflow, Cardionomics, Coridea, CVRx, Daxor, Deerfield Catalyst, Edwards LifeSciences, Echosens, EKO, Feldschuh Foundation, Fire1, FutureCardia, Galvani, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, Intershunt, Medtronic, Merck, NIMedical, NovoNordisk, NucleusRx, NXT Biomedical, Orchestra, Pharmacosmos, PreHealth, Presidio, Procyreon, ReCor, Rockley, SCPharma, Shifamed, Splendo, Summacor, SyMap, Verily, Vironix, Viscardia, and Zoll. All other authors have no relevant financial disclosures., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF